241 related articles for article (PubMed ID: 28838174)
21. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
[TBL] [Abstract][Full Text] [Related]
22. Introduction of Inactivated Poliovirus Vaccine in National Immunization Program and Polio Endgame Strategy.
; Vashishtha VM; Choudhary J; Yadav S; Unni JC; Jog P; Kamath SS; Sachdeva A; Srirampur S; Prajapati B; Parekh BJ
Indian Pediatr; 2016 Aug; 53 Suppl 1():S65-S69. PubMed ID: 27133231
[TBL] [Abstract][Full Text] [Related]
23. Anti-polio vaccinations in the third millennia.
Icardi G; Tassinari F
Ann Ig; 2018; 30(4 Supple 1):11-15. PubMed ID: 30062374
[TBL] [Abstract][Full Text] [Related]
24. Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies.
Pan WK; Seidman JC; Ali A; Hoest C; Mason C; Mondal D; Knobler SL; Bessong P;
Vaccine; 2019 Jan; 37(2):352-365. PubMed ID: 30442479
[TBL] [Abstract][Full Text] [Related]
25. India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.
Haldar P; Agrawal P
Indian Pediatr; 2016 Aug; 53 Suppl 1():S44-S49. PubMed ID: 27771639
[TBL] [Abstract][Full Text] [Related]
26. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
[No Abstract] [Full Text] [Related]
27. Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.
Pedreira C; Thrush E; Jauregui B
J Infect Dis; 2017 Jul; 216(suppl_1):S76-S85. PubMed ID: 28838161
[TBL] [Abstract][Full Text] [Related]
28. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
29. Strengthening the partnership between routine immunization and the global polio eradication initiative to achieve eradication and assure sustainability.
Abdelwahab J; Dietz V; Eggers R; Maher C; Olaniran M; Sandhu H; Vandelaer J
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S498-503. PubMed ID: 25316872
[TBL] [Abstract][Full Text] [Related]
30. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
31. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
[TBL] [Abstract][Full Text] [Related]
32. The new polio eradication end game: rationale and supporting evidence.
Sutter RW; Platt L; Mach O; Jafari H; Aylward RB
J Infect Dis; 2014 Nov; 210 Suppl 1():S434-8. PubMed ID: 25316865
[TBL] [Abstract][Full Text] [Related]
33. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
Khan MM; Sharma S; Tripathi B; Alvarez FP
Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
[TBL] [Abstract][Full Text] [Related]
34. Polio Endgame, Information Gaps Related to Vaccines and Immunity.
Ahmad M; Bahl S; Kunwar A
Indian Pediatr; 2016 Aug; 53 Suppl 1():S33-S37. PubMed ID: 27771637
[TBL] [Abstract][Full Text] [Related]
35. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
36. Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.
Chang C; Zhang J; Zhou J; Cao R; Song K; Liu C; Zhang X; Geng X; Liu X; Li C
Hum Vaccin Immunother; 2016 Nov; 12(11):2749-2752. PubMed ID: 27437792
[TBL] [Abstract][Full Text] [Related]
37. Global Polio Eradication,The Journey So Far.
Thacker N; Yewale VN; Pathak A
Indian Pediatr; 2016 Aug; 53 Suppl 1():S61-S64. PubMed ID: 27771642
[TBL] [Abstract][Full Text] [Related]
38. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Thompson KM; Kalkowska DA; Badizadegan K
Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
[TBL] [Abstract][Full Text] [Related]
39. Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned.
Decina D; Fournier-Caruana J; Takane M; Ostad Ali Dehaghi R; Sutter R
J Infect Dis; 2017 Jul; 216(suppl_1):S46-S51. PubMed ID: 28838164
[TBL] [Abstract][Full Text] [Related]
40. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
